Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?
29
Patients With ACS and Diabetes: How Can We Optimize Therapy?
description
Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?. Panelists. Learning Objectives. Learning Objectives. Diabetes as a CV Risk Factor. Impact of Gluco-Metabolic Characteristics on Risk of Major Cardiovascular Events. - PowerPoint PPT Presentation
Transcript of Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?
Secondary Prevention in Patients With ACS and Diabetes:
How Can We Optimize Therapy?
Panelists
Learning Objectives
Learning Objectives
Diabetes as a CV Risk Factor
Impact of Gluco-Metabolic Characteristics on Risk of Major
Cardiovascular Events
Risk Factors in Patients With T2D After ACS
The HDL Hypothesis
Meta-analysis of Intensive Statin Trials:
Coronary Death or Myocardial Infarction
Intensive Glucose Control in Critically Ill Patients: Death From
Any Cause
UKPDS: Extended Follow-up Benefits of Glycemic Control
Comparison of CETP Inhibitors
DAL-OUTCOMES: 3 Years
AIM-HIGH: End Point at 36-month Follow-up
ACCORD Lipid: Hazard Ratios for the Primary Outcome
SYNCHRONY: Effect of Aleglitazar on Cardiometabolic Parameters in
T2D
AleCardio: Aleglitazar in Patients With T2D and ACS
Unmet Needs: Diabetes in Post-ACS Patients
Abbreviations
Abbreviations (cont)
Abbreviations (cont)
References
References (cont)
References (cont)
References (cont)
